AU2010325787B2 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof - Google Patents

Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof Download PDF

Info

Publication number
AU2010325787B2
AU2010325787B2 AU2010325787A AU2010325787A AU2010325787B2 AU 2010325787 B2 AU2010325787 B2 AU 2010325787B2 AU 2010325787 A AU2010325787 A AU 2010325787A AU 2010325787 A AU2010325787 A AU 2010325787A AU 2010325787 B2 AU2010325787 B2 AU 2010325787B2
Authority
AU
Australia
Prior art keywords
factor viii
rfviiifc
dose
activity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010325787A
Other languages
English (en)
Other versions
AU2010325787A1 (en
AU2010325787A2 (en
AU2010325787A8 (en
Inventor
Alan J. Bitonti
Jennifer A. Dumont
Haiyan Jiang
Lian Li
Susan Low
Alvin Luk
Byron Mckinney
Karen Nugent
Matt Ottmer
Robert Peters
Glenn Pierce
Jurg Sommer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioverativ Therapeutics Inc
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of AU2010325787A1 publication Critical patent/AU2010325787A1/en
Publication of AU2010325787A8 publication Critical patent/AU2010325787A8/en
Publication of AU2010325787A2 publication Critical patent/AU2010325787A2/en
Assigned to BIOGEN HEMOPHILIA INC. reassignment BIOGEN HEMOPHILIA INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOGEN IDEC HEMOPHILIA INC.
Application granted granted Critical
Publication of AU2010325787B2 publication Critical patent/AU2010325787B2/en
Priority to AU2016213822A priority Critical patent/AU2016213822B2/en
Priority to AU2017268648A priority patent/AU2017268648B2/en
Assigned to BIOVERATIV THERAPEUTICS INC. reassignment BIOVERATIV THERAPEUTICS INC. Request to Amend Deed and Register Assignors: BIOGEN HEMOPHILIA INC.
Priority to AU2019202969A priority patent/AU2019202969A1/en
Priority to AU2021202912A priority patent/AU2021202912B2/en
Priority to AU2024227757A priority patent/AU2024227757A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010325787A 2009-12-06 2010-12-06 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof Active AU2010325787B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2016213822A AU2016213822B2 (en) 2009-12-06 2016-08-11 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2017268648A AU2017268648B2 (en) 2009-12-06 2017-11-30 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2019202969A AU2019202969A1 (en) 2009-12-06 2019-04-29 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2021202912A AU2021202912B2 (en) 2009-12-06 2021-05-07 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2024227757A AU2024227757A1 (en) 2009-12-06 2024-10-30 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US61/267,070 2009-12-06
US28505409P 2009-12-09 2009-12-09
US61/285,054 2009-12-09
US30159210P 2010-02-04 2010-02-04
US61/301,592 2010-02-04
US36306510P 2010-07-09 2010-07-09
US61/363,065 2010-07-09
US37311310P 2010-08-12 2010-08-12
US61/373,113 2010-08-12
US41092910P 2010-11-07 2010-11-07
US61/410,929 2010-11-07
US41967610P 2010-12-03 2010-12-03
US61/419,676 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016213822A Division AU2016213822B2 (en) 2009-12-06 2016-08-11 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof

Publications (4)

Publication Number Publication Date
AU2010325787A1 AU2010325787A1 (en) 2012-07-12
AU2010325787A8 AU2010325787A8 (en) 2012-07-19
AU2010325787A2 AU2010325787A2 (en) 2013-06-06
AU2010325787B2 true AU2010325787B2 (en) 2016-05-12

Family

ID=44115536

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2010325787A Active AU2010325787B2 (en) 2009-12-06 2010-12-06 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2016213822A Active AU2016213822B2 (en) 2009-12-06 2016-08-11 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2017268648A Active AU2017268648B2 (en) 2009-12-06 2017-11-30 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2019202969A Abandoned AU2019202969A1 (en) 2009-12-06 2019-04-29 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2021202912A Active AU2021202912B2 (en) 2009-12-06 2021-05-07 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2024227757A Pending AU2024227757A1 (en) 2009-12-06 2024-10-30 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2016213822A Active AU2016213822B2 (en) 2009-12-06 2016-08-11 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2017268648A Active AU2017268648B2 (en) 2009-12-06 2017-11-30 Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2019202969A Abandoned AU2019202969A1 (en) 2009-12-06 2019-04-29 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2021202912A Active AU2021202912B2 (en) 2009-12-06 2021-05-07 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2024227757A Pending AU2024227757A1 (en) 2009-12-06 2024-10-30 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

Country Status (30)

Country Link
US (5) US9050318B2 (enExample)
EP (4) EP4382170A3 (enExample)
JP (8) JP5903048B2 (enExample)
KR (1) KR101770849B1 (enExample)
CN (1) CN102791285A (enExample)
AU (6) AU2010325787B2 (enExample)
BR (1) BR112012013502A2 (enExample)
CA (2) CA3121739A1 (enExample)
CO (1) CO6561782A2 (enExample)
CY (2) CY1119919T1 (enExample)
DK (1) DK2506868T3 (enExample)
EA (2) EA025416B1 (enExample)
ES (2) ES2659888T3 (enExample)
HR (2) HRP20180135T1 (enExample)
HU (1) HUE036233T2 (enExample)
IL (2) IL220204B (enExample)
LT (1) LT2506868T (enExample)
ME (1) ME02964B (enExample)
MX (3) MX382693B (enExample)
MY (1) MY159135A (enExample)
NO (1) NO2506868T3 (enExample)
NZ (2) NZ600709A (enExample)
PL (2) PL3326643T3 (enExample)
PT (2) PT3326643T (enExample)
RS (1) RS56957B1 (enExample)
SG (3) SG181130A1 (enExample)
SI (1) SI2506868T1 (enExample)
SM (1) SMT201800099T1 (enExample)
WO (1) WO2011069164A2 (enExample)
ZA (1) ZA201204874B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP4169525A1 (en) * 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EA028914B1 (ru) * 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EA038705B1 (ru) * 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP3521321B1 (en) 2012-04-11 2020-11-04 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
US10023628B2 (en) * 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
RS61387B2 (sr) * 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3003368A4 (en) 2013-05-24 2017-05-03 Biogen MA Inc. Anti-gpiib/iiia antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
EA037962B1 (ru) * 2013-06-20 2021-06-16 Баксалта Инкорпорейтед Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
HK1223303A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 凝血酶可裂解连接子
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) * 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
KR20190072663A (ko) 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
JP6877469B2 (ja) * 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
BR112019002039A2 (pt) 2016-08-05 2019-05-07 Medimmune, Llc anticorpos anti-o2 e uso dos mesmos
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CA3039686A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
BR112019015569A2 (pt) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. Proteínas de fusão do fator ix e métodos para a sua produção e uso
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
EP3850006A1 (en) 2018-09-11 2021-07-21 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
IL316578A (en) * 2022-04-28 2024-12-01 Biocad Joint Stock Co Isolated nucleic acid encoding a FVIII-BDD-based coupling protein and a heterologous signal peptide
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147618A1 (en) * 2003-05-06 2005-07-07 Rivera Daniel S. Clotting factor-Fc chimeric proteins to treat hemophilia
US20050260194A1 (en) * 2003-05-06 2005-11-24 Peters Robert T Immunoglobulin chimeric monomer-dimer hybrids

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2437015A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1863556B (zh) * 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EA038705B1 (ru) * 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147618A1 (en) * 2003-05-06 2005-07-07 Rivera Daniel S. Clotting factor-Fc chimeric proteins to treat hemophilia
US20050260194A1 (en) * 2003-05-06 2005-11-24 Peters Robert T Immunoglobulin chimeric monomer-dimer hybrids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dumont, J.A. et al. Blood, 51st Annual Meeting of the American Society of Hematology; New Orleans, LA USA, 5-8 December 2009, Abstract No 545 *

Also Published As

Publication number Publication date
JP6062459B2 (ja) 2017-01-18
IL220204A0 (en) 2012-07-31
ES2659888T3 (es) 2018-03-19
AU2010325787A1 (en) 2012-07-12
US9241978B2 (en) 2016-01-26
AU2016213822B2 (en) 2017-08-31
NZ600709A (en) 2015-01-30
AU2019202969A1 (en) 2019-05-16
SI2506868T1 (en) 2018-04-30
EP3906937A1 (en) 2021-11-10
SG10201408049SA (en) 2015-02-27
CA2782424A1 (en) 2011-06-09
EP2506868B1 (en) 2017-11-15
EP4382170A2 (en) 2024-06-12
SG181130A1 (en) 2012-07-30
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
EP4382170A3 (en) 2024-09-04
AU2017268648B2 (en) 2019-01-31
BR112012013502A2 (pt) 2017-01-10
JP2015083608A (ja) 2015-04-30
NO2506868T3 (enExample) 2018-04-14
US20130274194A1 (en) 2013-10-17
CO6561782A2 (es) 2012-11-15
JP2025083451A (ja) 2025-05-30
PT3326643T (pt) 2021-07-12
AU2017268648A1 (en) 2017-12-21
CA2782424C (en) 2021-07-27
EP2506868A4 (en) 2013-07-24
ES2880038T3 (es) 2021-11-23
DK2506868T3 (da) 2018-01-29
PT2506868T (pt) 2018-02-23
CN102791285A (zh) 2012-11-21
LT2506868T (lt) 2018-02-26
US9050318B2 (en) 2015-06-09
HRP20180135T1 (hr) 2018-04-06
JP6385410B2 (ja) 2018-09-05
US20220265780A1 (en) 2022-08-25
HUE036233T2 (hu) 2018-06-28
US20190262429A1 (en) 2019-08-29
AU2021202912B2 (en) 2024-08-01
HRP20211010T1 (hr) 2021-09-17
SG10201907152YA (en) 2019-09-27
JP2013512678A (ja) 2013-04-18
RS56957B1 (sr) 2018-05-31
IL260769B (en) 2020-03-31
AU2024227757A1 (en) 2024-11-21
JP2020019821A (ja) 2020-02-06
MX336830B (es) 2016-02-03
NZ703153A (en) 2015-02-27
US20160199455A1 (en) 2016-07-14
JP2023071969A (ja) 2023-05-23
AU2016213822A1 (en) 2016-09-01
AU2010325787A2 (en) 2013-06-06
WO2011069164A2 (en) 2011-06-09
JP7244688B2 (ja) 2023-03-22
SMT201800099T1 (it) 2018-03-08
JP2022051964A (ja) 2022-04-01
PL2506868T3 (pl) 2018-06-29
JP2017025098A (ja) 2017-02-02
EA025416B1 (ru) 2016-12-30
ME02964B (me) 2018-07-20
CA3121739A1 (en) 2011-06-09
EP2506868A2 (en) 2012-10-10
JP6641340B2 (ja) 2020-02-05
HK1253887A1 (en) 2019-07-05
MY159135A (en) 2016-12-15
JP2018024706A (ja) 2018-02-15
MX353233B (es) 2018-01-08
US11266720B2 (en) 2022-03-08
IL220204B (en) 2018-08-30
ZA201204874B (en) 2016-06-29
KR20120129882A (ko) 2012-11-28
WO2011069164A3 (en) 2011-07-28
EA038618B1 (ru) 2021-09-23
EA201691109A1 (ru) 2017-01-30
EA201290443A1 (ru) 2013-06-28
AU2010325787A8 (en) 2012-07-19
JP5903048B2 (ja) 2016-04-13
MX2012006347A (es) 2012-10-03
CY1119919T1 (el) 2018-06-27
EP3326643B1 (en) 2021-04-07
AU2021202912A1 (en) 2021-06-03
US20130108629A1 (en) 2013-05-02
KR101770849B1 (ko) 2017-09-05
CY1124888T1 (el) 2023-01-05
EP3326643A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US20220265780A1 (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US20250195620A1 (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US11747351B2 (en) Assays to monitor bleeding disorders
US10391152B2 (en) Methods of using a fixed dose of a clotting factor
EA053047B1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
BR112014000466B1 (pt) Composição farmacêutica que compreende um polipeptídeo quimérico compreendendo uma porção do fator viii (fviii) e uso da mesma

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 26 , NO 26 , PAGE(S) 3504 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES BIOGEN IDEC HEMOPHILIA INC., APPLICATION NO. 2010325787, UNDER INID (72) CORRECT THE CO-INVENTORS TO MCKINNEY, BYRON; SOMMER, JURG

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 DEC 2012 AND 8 MAY 2013

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BIOVERATIV THERAPEUTICS INC.

Free format text: FORMER NAME(S): BIOGEN HEMOPHILIA INC.